Natural killer cell education does not affect the magnitude of granzyme B delivery to target cells by antibody-dependent cellular cytotoxicity

AIDS

Volumn 29, Issue 12, 2015, Pages 1433-1443

  Isitman, Gamze ^a,b   Lisovsky, Irene ^a,b   Tremblay McLean, Alexandra ^a,b   Parsons, Matthew S ^c   Shoukry, Naglaa H ^d   Wainberg, Mark A ^e   Bruneau, Julie ^d,f   Bernard, Nicole F ^a,b,g,h  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g Chronic Viral Illness Service   (Canada)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

antibody dependent cellular cytotoxicity; CD16; granzyme B; human leukocyte antigen; killer immunoglobulin like receptors; natural killer cells

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 120; GRANZYME B; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; CCL4 PROTEIN, HUMAN; GRANZYME; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1BETA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN CELL; LYMPHOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; TARGET CELL; CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELLS, CULTURED; CHEMOKINE CCL4; GRANZYMES; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1;

EID: 84942588423     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000729     Document Type: Article

References (71)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-376.
2. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song Y-J, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436:709-713.
3. Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-342.
4. Faure M, Barber DF, Takahashi SM, Jin T, Long EO. Spontaneous clustering and tyrosine phosphorylation of NK cell inhibitory receptor induced by ligand binding. J Immunol 2003; 170: 6107-6114.
5. Long EO. Regulation of immune responses through inhibitory receptors. Ann Rev Immunol 1999; 17:875-904.
6. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 2008; 224:70-84.
7. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009; 114:2657-2666.
8. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med 2005; 202:1001-1012.
9. Fauriat C, IvarssonMA, LjunggrenHG,Malmberg KJ,Michaelsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010; 115:1166-1174.
10. Ciccone E, Pende D, Vitale M, Nanni L, Di Donato C, Bottino C, et al. Self class I molecules protect normal cells from lysis mediated by autologous natural killer cells. Eur J Immunol 1994; 24:1003-1006.
11. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994; 180:1235-1242.
12. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 1995; 181:1133-1144.
13. Wan AM, Ennis P, Parham P, Holmes N. The primary structure of HLA-A32 suggests a region involved in formation of the Bw4/Bw6 epitopes. J Immunol 1986; 137:3671-3674.
14. Kim S, Sunwoo JB, Yang L, Choi T, Song Y-J, French AR, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 2008; 105:3053-3058.
15. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 10:661-671.
16. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998; 391:397-401.
17. Ward JP, Bonaparte MI, Barker E. HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. AIDS 2004; 18:1769-1779.
18. Brodin P, Lakshmikanth T, Johansson S, Karre K, Hoglund P. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood 2009; 113:2434-2441.
19. Bryceson YT, Chiang SC, Darmanin S, Fauriat C, Schlums H, Theorell J, et al. Molecular mechanisms of natural killer cell activation. J Innate Immun 2011; 3:216-226.
20. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005; 105:4416-4423.
21. Johansson S, Johansson M, Rosmaraki E, Vahlne G, Mehr R, Salmon-Divon M, et al. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med 2005; 201:1145-1155.
22. Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the Rheostat model. J Immunol 2009; 182:4572-4580.
23. Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, French AR, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 2008; 105:3053-3058.
24. Boulet S, Song R, Kamya P, Bruneau J, Shoukry NH, Tsoukas CM, et al. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLAdevoid cells. J Immunol 2010; 184:2057-2064.
25. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-740.
26. Kamya P, Boulet S, Tsoukas CM, Routy J-P, Thomas R, Cǒté P, et al. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1Mh/My and HLA-BM57. J Virol 2011; 85:5949-5960.
27. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001; 75:6953-6961.
28. Hessell AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104.
29. Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M Jr., Carville A, et al. ADCC develops over time during persistent infection with live-Attenuated SIV and is associated with complete protection against SIVmac251 challenge. PLoS Pathog 2012; 8:e1002890.
30. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-1286.
31. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
32. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178:6596-6603.
33. Brocca-Cofano E, McKinnon K, Demberg T, Venzon D, Hidajat R, Xiao P, et al. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 2011; 29:3310-3319.
34. FloreseRH, Van Rompay KK, Aldrich K, ForthalDN, Landucci G, Mahalanabis M, et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006; 177:4028-4036.
35. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-954.
36. Palermo RE, Patterson LJ, Aicher LD, Korth MJ, Robert-Guroff M, Katze MG. Genomic analysis reveals pre and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy. J Virol 2011; 85:1099-1116.
37. Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA, Venzon D, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol 2012; 86:4644-4657.
38. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010; 84:7161-7173.
39. Ahmad R, Sindhu SAK, Toma E, Morisset R, Vincelette J, Menezes J, et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001; 21:227-233.
40. Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, et al. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad SciUS A 2011; 108:7505-7510.
41. Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, Hoxie JA, et al. High-throughput quantitative analysis of HIV-1 and SIVspecific ADCC-mediating antibody responses. Cytometry A 2011; 79:603-612.
42. Gooneratne SL, Richard J, Lee WS, Finzi A, Kent SJ, Parsons MS. Slaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T-cells. LID J Virol 2014; 89:97-109.
43. Parsons MS, Wren L, Isitman G, Navis M, Stratov I, Bernard NF, et al. HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity. J Virol 2012; 86:4488-4495.
44. Parsons MS, Zipperlen K, Gallant M, Grant M. Killer cell immunoglobulin-like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells. J Leukoc Biol 2010; 88:905-912.
45. Smalls-Mantey A, Connors M, Sattentau QJ. Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils. PLoS One 2013; 8:e74858.
46. Kantakamalakul W, Pattanapanyasat K, Jongrakthaitae S, Assawadarachai V, Ampol S, Sutthent R. A novel EGFP-CEM-NKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV-1 infected individuals. J Immunol Methods 2006; 315:1-10.
47. Richard J, Veillette M, Batraville LA, Coutu M, Chapleau JP, Bonsignori M, et al. Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. J Virol Methods 2014; 208:107-114.
48. Boulet S, Sharafi S, Simic N, Bruneau J, Routy J-P, Tsoukas CM, et al. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008; 22:595-599.
49. Boulet S, Kleyman M, Kim JYJ, Kamya P, Sharafi S, Simic N, et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-BM57 is associated with a reduced risk of HIV infection. AIDS 2008; 22:1487-1491.
50. Boulassel MR, Spurll G, Rouleau D, Tremblay C, Edwardes M, Sekaly RP, et al. Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis. J Clin Apher 2003; 18:55-60.
51. Howell DN, Andreotti PE, Dawson JR, Cresswell P. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol 1985; 134:971-976.
52. Lyerly HK, Reed DL, Matthews TJ, Langlois AJ, Ahearne PA, Petteway SR Jr., et al. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses 1987; 3:409-422.
53. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP. A cell linebased neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 1999; 73:8966-8974.
54. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol 2009; 182:1202-1210.
55. Madhavi V, Navis M, Chung AW, Isitman G, Wren LH, De Rose R, et al. Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes. Hum Vaccin Immunother 2013; 9:1011-1018.
56. Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 2008; 82:5450-5459.
57. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 2005; 106:3366-3369.
58. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, Planta MA, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A 2003; 100:15011-15016.
59. Pham TNQ, Lukhele S, Hajjar F, Routy J-P, Cohen EA. HIV Nef and Vpu protect HIV-infected CD4R T cells from antibodymediated cell lysis through down-modulation of CD4 and BST2. Retrovirology 2014; 11:15-115.
60. Veillette M, Coutu M, Richard J, Batraville L-A, Dagher O, Bernard N, et al. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol 2015; 89:545-551.
61. Veillette M, Désormeaux A, Medjahed H, Gharsallah N-E, Coutu M, Baalwa J, et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cellmediated cytotoxicity. J Virol 2014; 88:2633-2644.
62. Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles SA, Ko S-Y, et al. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4R T cells is directly associated with the magnitude of surface IgG binding. J Virol 2012; 86:8672-8680.
63. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1-And NK2-specific natural killer cells. Proc Natl Acad Sci U S A 1993; 90:12000-12004.
64. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16RNK-cell subset. Blood 2010; 116:3865-3874.
65. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 2012; 24:331-341.
66. ParsonsMS, TangCC, Jegaskanda S,Center RJ, BrooksAG, Stratov I, et al. Anti-HIV antibody-dependent activation of NK cells impairs NKp46 expression. J Immunol 2014; 192:308-315.
67. Kramski M, Parsons M, Stratov I, Kent SJ. HIV-specific antibody immunity mediated through NK cells and monocytes. Curr HIV Res 2013; 11:388-406.
68. Kramski M, Schorcht A, Johnston APR, Lichtfuss GF, Jegaskanda S, De Rose R, et al. Role of monocytes in mediating HIVspecific antibody-dependent cellular cytotoxicity. J Immunol Meth 2012; 384:51-61.
69. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang K-K, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012; 86:11521-11532.
70. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011; 85:7029-7036.
71. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci 2013; 110:E69-E78.